TNBC, identified as lacking human epidermal growth factor receptor 2 (HER2) overexpression and functional expression of estrogen and progesterone receptors, is the breast cancer (BC) subtype with the poorest clinical outcome1,2. This evidence concerns the gene ERBB2 and breast carcinoma.